GlobeNewswire Inc.··Telix Pharmaceuticals LimitedTelix Hits Dosing Milestone in Glioblastoma Study as Radiopharmaceutical Therapy Advances
Telix Pharmaceuticals completes enrollment in IPAX-2 glioblastoma study, reaching maximum 10GBq dose with no toxicities observed. Phase 3 trial advancement marks first radiopharmaceutical therapy for this indication.
TLXPhase 3 trialorphan drug designation